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The survey had the following aims: (1) to rationalise the hypothesis that risks and losses relating to medication
process' errors in Czech hospitals are at least comparable with the other developed countries and EU countries
especially, (2) to get a valid professional opinion/estimate on the rate of adverse drug events happening in Czech
hospitals, (3) to point out that medication errors represent real and serious risks and (4) to induce the hospital
management readiness to execute fundamental changes and improvements to medication processes. We read
through a lot of studies inquiring into hospitals' medication safety. Then, we selected the studies which brought
reliable findings and formulated credible conclusions. Finally, we addressed reputable Czech experts in health care
and asked them structured questions whether the studies' findings and conclusions corresponded with our
respondents' own experience in the Czech hospital clinical practice and what their own estimates of adverse drug
events' consequences were like. Based on the reputable Czech health care expert opinions/estimates, the rate of a
false drug administration may exceed 5%, and over 7% of those cause serious health complications to Czech
hospital inpatients. Measured by an average length of stay (ALOS), the Czech inpatients, harmed by a false drug
administration, stay in hospital for more than 2.6 days longer than necessary. Any positive changes to a currently
used, traditional, ways of drug dispensing and administration, along with computerisation, automation, electronic
traceability, validation, or verification, must well pay off. Referring to the above results, it seems to be wise to follow
the EU priorities in health and health care improvements. Thus, a right usage of the financial means provided by
the EC—in terms of its new health programmes for the period 2014–2020 (e.g. Horizon 2020)—has a good chance
of a good result in doing the right things right, at the right time and in the right way. All citizens of the EU may
benefit using the best practice.
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Introduction
It is surprising that—despite tremendous progress in
pharmaceutics, diagnostics, surgery or other medical tech-
nologies—there has been hardly any advance in medica-
tion process in Czech (European) hospitals for many
decades, as though the technology and progress avoided
the medication processes. The reality is, however, contrary
to fact that medication has a much wider choice in drugs
with much stronger treatment effects than those a couple
of years ago. However, progress in medicament efficiency
also brings much stronger, undesirable, or excessive side
effects at the same time. This is one of the reasons why a
medication of inpatients in hospitals may be considered
quite a risky process which has been documented and
proven by a number of serious studies performed
worldwide. Most of the damage is caused by human
factor failures, i.e. errors made during a traditional drug
administration process used in prevailing part of EU hos-
pitals and currently in all hospitals of the Czech Republic.
In order to transfer the international experience into the
Czech health care environment and to show that this sub-
ject is important for both the inpatients' safety and their
treatment efficiency, I have initiated and performed a spe-
cial survey based on the Czech Republic reputable experts'
opinions.
Topic-related overview
At the end of 2012, the ‘General report & recommenda-
tions in predictive, preventive and personalised medicine
2012: white paper of the European Association for Pre-
dictive, Preventive and Personalised Medicine’ [1] was is-
sued. It was a kind of a good international momentum
initiating a new approach to modern medicine percep-
tion, definition and institutionalisation. The White Paper
also comprises the ‘Patient-Specific Modelling’ part, which
depicts the multifunctional and interdisciplinary approach
necessary for clinical application of personalised medicine.Table 1 Some examples of extensive studies' results (focused









Sweden 2003–2004The individualised patient records and patient models,
individualised therapy with medical/technical systems and
IT-assisted processes represented the major topics, closely
related to this article contents.
Errors and adverse events happen in all kinds and
forms of medical care, or all types of health care work-
places. That is the reason why it is not surprising that
there is a wide spectrum of studies using different meth-
odologies and bringing a wide range of results. All the
studies performed have one point in common—the
errors and adverse events are a very frequent and con-
siderable problem in all types of institutions, where the
errors were tracked [2] (Table 1).
The European Commission (EC) pays quite a lot of at-
tention to the patient safety and quality of health care.
There are good reasons for this. Based on its own stud-
ies performed in recent years, EC found out that an esti-
mated 8%–12% of patients admitted to hospitals in the
EU suffer from adverse events whilst receiving health
care (e.g. health care-associated infections amounting to
approximately 25% of adverse events, medication-related
errors, surgical errors, medical device failures, errors in
diagnosis and failure to act on the results of tests). Much
of the patients' harm is preventable, but the implementa-
tion of strategies to reduce harm varies widely across the
EU [3]. The present article focuses on the medication-
related errors and their consequences, and it suggests
some possibilities to prevent them efficiently.
Other extensive studies confirm that failures and er-
rors happening during therapy represent quite a serious
problem with serious consequences. The ‘Harvard Med-
ical Practice Study’ [4] reviewed 30,121 randomly se-
lected case records of inpatients hospitalised during
1984 in 51 randomly chosen hospitals providing acute
health care (excluding psychiatric departments) in the
state of New York. Adverse events were defined as dam-
age caused by the therapy and treatment used in provid-
















Figure 1 Types and percentage share of errors recorded.
Veselik The EPMA Journal 2014, 5:7 Page 3 of 13
http://www.epmajournal.com/content/5/1/7extension of the patient's hospitalisation. Such adverse
events were found at 3.7% of all hospitalisation cases,
and 27.6% of them were caused by inadvertency of the
care-providing personnel. The adverse drug events were
the most frequently occurring non-surgical errors; the
diagnostics' failures, errors in therapy care, etc. followed.
Of all identified adverse events, 6.5% lead to patients' per-
manent disability, and 13.6% to patients' death. Two years
later, the same team performed a follow-up study focused
on preventing medical injury and found that 69.6% of the
adverse events mentioned were preventable.
The Utah and Colorado medical practice study [5]
done in 1992 assessed 14,052 randomly selected closed-
case records in randomly chosen hospitals (Utah and
Colorado, USA). The study proved that 2.9% of the inpa-
tients had been harmed by adverse events, while about
30% had been caused by neglect, and about 50% had
been preventable. The surgical errors represented 44.9%,
the adverse drug events totalled to 19.3%. Of all the ad-
verse events, 8.4% lead to a patient's permanent disabil-
ity, and 6.6% of the harmed patients died.
Formerly elaborated (in 1974), The California Medical
Insurance Feasibility Study [6] similarly identified, in
20,864 finished case records, 4.65% patients who suf-
fered a preventable health damage by their medical ther-
apy. In 1992, ‘The quality in Australian healthcare study’
[7] found that adverse events happen in 16.6% of all hos-
pitalisations, while 51% of them were marked as prevent-
able. The majority of errors were found in surgical
procedures, 13.6% in diagnostics, 12.0% in therapy and
10.8% in adverse drug events. In consequence of adverse
events, 13.7% of inpatients were permanently disabled,
and 4.9% of the inpatients died.
In order to find a way how to draw attention to im-
prove medication safety, we focused on the adverse drug
event incidence. The adverse events caused by medica-
tion errors that harm inpatients during their hospitalisa-
tion represent a specific group of preventable failures.
Researching and analysing various studies on medication
safety, medication errors, or adverse drug events [8-25],
we have tried to spot such studies which provided well-
footed results identifying the following:
1. rate of the adverse drug event (ADE) incidence in
hospitals using a traditional process of medication
(none or not fully used, computerised patient order
entry (CPOE), a decentralised non-automated drug
administration, none or rare electronic bedside veri-
fications of correct dispensing),
2. rate of ADE causing a serious health damage to
hospital inpatients,
3. consequences of serious health damage caused by
ADE (in terms of an extended stay of a patient in
hospital and/or the extended care induced by ADE).Generally, all the studies we read through had one fea-
ture in common. The more consistent and thorough the
studies' observations, the higher rate of adverse drug
events and the more serious consequences of them were
registered. Seeking the ADE in a form of a well-executed
study, we have identified three. Each of them provided
the required ADE information and answered one of the
above mentioned questions.Reference study 1: performed by the Municipal Hospital
in Munich in 2004
The study was performed by the Municipal Hospital in
Munich (Städtisches Krankenhaus München-Harlaching)
in 2004 [26]. More information about the study can be
found at http://www.adka.de/solva_docs/341_altersber-
ger_poster_weimar.pdf. It focused on medication error
incidence especially. It was an inspection or rather
examination performed by the hospital for themselves in
order to detect their own errors in medication and to
identify possibilities for improvements. It was performed
for 1 day at 12 wards. The prescriptions and administra-
tion of 868 items of drugs to 189 patients (4.6 drug
items per patient) were examined. The study focused on
both the errors in drug prescription (first part) and the
errors in drug administration (second part). Out of the
868 drug item prescriptions, 76 had some errors (8.8%)
as shown in Figure 1.
The types of wrong dispensing instructions were fur-
ther detailed in Table 2.
The errors made during the drug dispensing were
assessed in the second part of the study. The hospital
pharmacist visited the relevant hospital departments
without any prior notice and checked and recorded di-
vergences from the given prescription. The assessment
was performed directly, and/or after the drug adminis-
tration to a patient, and it brought the results shown in
Figure 2 and Table 3.
Table 2 Wrong dispensing instructions in detail
Instruction Percentage
Wrong dosage 10
Wrong interval for dispensing 10
Wrong medication tenure 10
No reflection of the patient's liver and kidney testing 5










Wrong drug 12 27 1.38
Wrong dosage 11 25 1.26
Wrong time 3 6 0.34
Wrong patient 2 4 0.23




Total 43 100 4.95
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istered, and at least one of the above defined errors was
made, i.e. there was a breach of rules and patients' rights
set by the Joint Commission International (JCI). We
have also selected and used this study as reference study
1 because the German hospitals (as well as the Czech
ones) widely use a traditional, decentralised and manual
drug dispensing at their hospital wards. So, the study re-
sults may be fairly considered very similarly to those of
the Czech hospitals. This study was cited, and its results
were used in the ‘Hospital management of the future:
knowledge and recommendations of experts’ [27], and
there is a good example of a rather shocking impact of
medication errors on patients' safety in chapter 26.1
[28]. We used a similar example in the ‘Summary’ sec-
tion of this article.Reference study 2: performed in 36 US hospitals in 2002
Here, we refer to the study ‘Medication errors observed
in 36 health care facilities’ performed in 36 USA hospi-
tals in 2002. The results were published in The Journal
of the American Medical Association [29]. The goal ofFigure 2 Errors made during drug dispensing.the study was to identify the prevalence of medication
errors (doses administered differently from those or-
dered). The study was performed as a prospective cohort
study on the data from hospitals accredited by the Joint
Commission on Accreditation of Healthcare Organiza-
tions, non-accredited hospitals, and skilled nursing facil-
ities in Georgia and Colorado. The study participants
were selected in a format of a stratified random sample
of 36 institutions. Twenty-six declined, with random
replacement.
Medication doses given (or omitted) during at least
one medication pass during a 1- to 4-day period by
nurses on high-medication-volume nursing units. The
target sample was 50 day-shift doses per nursing unit or
until all doses for that medication pass were adminis-
tered. Medication errors were witnessed by observation
and verified by a research pharmacist (E.A.F.).
Clinical significance was judged by an expert panel of
physicians. The study focused on measuring medication
errors committed on patients, and it came to the follow-
ing results: In 36 institutions, 19% of the doses (605/
3,216) were erroneous. The most frequent errors by cat-
egory were wrong time (43%), omission (30%), wrong
dose (17%) and unauthorised drug (4%). Seven percent
of the errors were considered as potential adverse drug
events. There was no significant difference between
error rates in the three settings (P = 0.82) or by size (P =
0.39). The error rates were higher in Colorado than in
Georgia (P = 0.04). The main conclusions of the study
were following: Medication errors were common (nearly
one in every five doses in a typical hospital and skilled
nursing facility). Potential clinical significance for each
error category in the study results was assessed, as
shown in Table 4.
The percentage of errors rated potentially harmful was
7%, or more than 40 errors per day in a typical 300-
patient facility. The problem of defective medication ad-
ministration systems, although varied, was clearly de-
clared as widespread.
Table 4 Clinical significance for each error category






Dose 8 1 9 11
Omission 271 17 288 6
Unauthorized drug 24 4 28 14
Wrong dose 84 15 99 15
Wrong form 12 6 18 33
Wrong route 4 1 5 20
Wrong technique 0 1 1 100
Wrong time 224 3 227 1
Total 627 48 675 7
Table 5 Length of extra hospitalisation stay caused by
adverse drug events





Mean ± SD 12.7 ± 17.2 9.8 ± 11.6 2.9
Median (Q1–Q3) 8.0 (4.0–15.0) 7.0 (3.0–13.0) 1.0
Range 0–273 0–161 –
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Germany in 2012
In this case, we refer to the study ‘Costs of Adverse Drug
Events in German Hospitals—A Microcosting Study’
[30] by Dominik Rottenkolber, MBR, Joerg Hasford,
MD, and Jürgen Stausberg, MD in 2012. The aim of this
study was twofold: first, to calculate the direct treatment
costs associated with ADEs leading to hospitalisation
and second, to derive the excess costs and extra hospital
days attributable to ADEs of inpatient treatments in se-
lected German hospitals. While the hospital cost struc-
ture, proportions and height in Germany differ from those
in Czech Republic, we were ‘only’ interested in the part of
the study where it tried to identify the extra days of hospi-
talisation of patients hurt by adverse drug events.
In 2012, an extensive research as one of the first adminis-
trative data-based analyses calculating the economic conse-
quences of ADEs in Germany was performed. The study
focused on costs of wrong medication causing adverse
drug events and their therapeutic remedies/corrections. It
was a retrospective and medical record-based study per-
formed from the hospitals' perspective based on adminis-
trative accounting data from three hospitals in Germany
(49,462 patients were hospitalised there in 2008). Analysis
used clinical, demographic and economic data in order to
describe the patient sample and calculate their therapy
costs. Classification of diagnoses referred to the German
modification of ICD-10 used for coding inpatients of Ger-
man hospitals. The average length of stay (ALOS) of the
patients was between 6.8 to 8.7 days which is similar to the
ALOS typical of patients of Czech hospitals. One of the
study outcomes important for our survey purposes was
that the average length of extra hospitalisation stay caused
by adverse drug events was 2.9 days (Table 5).
The study results highlighted considerable extra costs
resulting from ADEs. So, the authors of this study, as
well as the authors of the other studies mentioned in thisarticle, believe that these study results may support
health-policy decision makers in allocating research grants
assessing the impact of ADEs on European health care
systems, to help find efficient provisions predicting or pre-
venting ADEs or pushing ahead personalised and safe
medication procedures for the EU citizens/patients.
When thinking about mitigation, and/or elimination of
the above risks, you will come to a couple of common
denominators, like computerised physician's order entry,
structured medication, data electronic digitalisation, bar
coding, two-dimensional coding and automation. Many
serious studies give us quite a clear message.
For instance, the study ‘Effect of bar-code technology
on the safety of medication administration’ [31] proved
that the implementation of structured medication and
bar coding in drug management had
 completely eliminated errors arising during
transcriptions of physicians' order entries,
 decreased errors in a timely drug administration
by 27%,
 lowered all the other types of errors in drug
administration by 41%,
 brought down the potential incidence of ADEs
by 51%.
However, even a highly computerised medication process
cannot bring a total elimination of errors. High rates of
ADEs may continue to occur after the implementation of
CPOE and the related computerised medication systems
that lack decision support for drug selection, dosing and
monitoring [32]. On the other hand, the whole portfolio of
errors has changed substantially: majority of the errors
made during drug administration and drug dispensing has
been reduced to a very minimum (administration to 13%,
dispensing to 1%, transcription to 0%), while the prevailing
part of the remaining errors consists of ordering (61%) and
monitoring (25%). Errors in ordering are also preventable,
but by means of a pharmacologists' and pharmacists' valid-
ation which is effectively contingent on the CPOE and by a
possible use of sophisticated software tools. So, the person-
alisation and electronic digitalisation of data is a must for
really modern innovation in medication process and opens
the door to an effective interdisciplinary collaboration
within major health care processes.
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Upon discussions about medication safety in hospitals
held with a number of reputable Czech health care ex-
perts, it was agreed that innovation of a traditionally
used medication process in Czech hospitals made good
sense, and the topic deserved a special attention. How-
ever, as soon as you tried to quantify possible benefits of
such innovation, you will find a lack, and/or absence of
studies performed in the Czech Republic health care sys-
tem in a scope and way which would provide reliable
and reliable results or conclusions.
As noted in the previous section, there are many stud-
ies on the topic of medication errors and their conse-
quences in hospitals performed worldwide, but for the
Czech hospital managers and decision makers, the
studies represented just something which may be valid
in other health care systems and in a different environ-
ment, however, not as much in the Czech health care
system and its specific environment. The managers
have been quite well aware of the time, efforts, work-
load and financial demands of any change to a trad-
itional, more or less well functioning, medication
process used for many decades. When you want to con-
vince the managers of such an investment's pay-off, you
needed to come up with something which is reliable
and persuasive. In other words, you have to bring good
arguments from the Czech hospitals directly, not
vicariously.
With no other possibility or sufficient financial fund-
ing for elaboration on a Czech thorough study of Czech
hospitals, the present author has decided to use high-
quality foreign study results and compare them with the
Czech hospitals' real situation by means of expert opin-
ions. In order to perform such a comparison, we have
addressed reputable Czech experts in health care. We
selected those with long-time clinical experience won at
various positions held in Czech hospitals (medical doc-
tors/physicians, clinical researchers and scientists, nurses
in chief, pharmacists, hospital directors and other distin-
guished persons, including ministers of health, medical
faculty deans, and/or university principal/chancellor).
All the foreign studies selected had the following
major characteristics:
 were focused on medication processes identical with
or very similar to those used in Czech hospitals,
 used a comprehensive and reliable methodology and
accurate and reliable data,
 provided lucid and credible results/conclusions at a
rather conservative level.
From a number of studies read through, we have se-
lected those ones which have the above characteristics
and provide answers to three crucial questions:1. What is the rate of medication errors (ADEs) made in
hospitals when providing hospital care to inpatients?
2. What is the rate of ADEs which may cause serious
negative effects to inpatients' health status, inducing
additional extra care or hospitalisation?
3. What are the measurable consequences of ADEs
causing serious negative effects to inpatients' health
status?
After the above types of study selection, the abstracts
have been prepared as well as references to full versions,
a structured questionnaire has been created and profes-
sional respondents have been asked to answer the fol-
lowing questions:
1. Is the study relevant to a real situation in Czech
hospitals?
2. Is the study methodology used for the identification
of ADEs reliable and logically correct?
3. Do you believe that the findings, results or
conclusions of the study apply to the situation in
Czech hospitals?
4. What number or percentage of interval do you
consider relevant to and expectable in the Czech
hospitals' environment?
Results
Expert opinions on the rate of medication errors
Additional file 1: Table S1 shows an overview of all re-
spondents' answers regardless of their professional sta-
tus. While the Munich Study came to the 4.9% share of
the ADEs out of all medication cases, the Czech experts
indicated their opinions based on their experience that
in Czech hospitals, the ADE may range from 4.37% (or
3.51%) to 8.65% (5.61%) with a mid-value of 6.51%
(5.61%). The numbers in parentheses represent values
after exclusion of one piece of the highest and one piece
of the lowest values out of all the values obtained. A vast
majority of the respondents considered the above refer-
ence study with high quality and fully applicable to the
Czech environment. The respondents' estimate even
showed their opinions that the rate of ADEs in Czech
hospitals might be higher than that suggested by the ref-
erence study.
Each of respondents had experience, at various posi-
tions, in hospital process managements; however, she or
he still represented primarily one of four possible profes-
sional groups. The four groups were physicians, nurses,
pharmacists and managers with non-medical educational
backgrounds. Professionally determined views have own
quite interesting features. For instance, the insight of ex-
perienced nurses present at each procedure of the medi-
cation process in person is non-neglectable [Additional
file 1]. Without attaching a higher or lower importance
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complementary information has been shown in the
present article.
Physicians apparently saw the above study as relevant
to Czech hospitals' real situation, and their estimates of
medication error rate reached the mid-values, the same
mid-values as those of the above reference study [see
Additional file 1: Table S2].
Nurses considered the methodology, realisation and re-
sults of the above study fully compatible with their experi-
ence in Czech hospitals [see Additional file 1: Table S3].
Their professional estimates of the medication error rate
came to much higher values than the above study. Pro-
vided you take into account the fact that nurses ensure
in person the medication process in hospitals and are
familiar with its peculiarities, the estimate has a non-
neglectable information value.
Pharmacists considered the above study methodology
and quality of its realisation reliable, and its findings
relevant for Czech health care's real situation. Their esti-
mates were—in comparison to the study findings—a bit
more conservative [see Additional file 1: Table S4).
Also, non-medical managers considered the study meth-
odology and quality of its realisation reliable, and its
findings relevant to the Czech health care [see Additional
file 1: Table S5). Their estimates were approximately at
the level showed by the above study.
Conclusions
Conclusion 1
In general, it is obvious that an absolute majority of our
respondents consider the Munich study well done, reli-
able, and with applicable results for practice in Czech
hospitals. An important part of the respondents consid-
ered a possible rate of medication errors in the Czech
environment rather higher than 5% out of all the admin-
istered drug volume.
Expert opinions on the rate of serious impacts caused by
wrong medication
As shown in Additional file 1: Table S6, a prevailing ma-
jority of respondents considered the above study meth-
odologically correct, well elaborated on, reliable and
applicable to the Czech environment (even though per-
formed in a very different health care system). The re-
spondents' estimate of the share of adverse drug events
out of the whole hospital medication practice seemed to
be slightly higher than that in the above study. The pro-
fessional groups' views differed a little from each other,
and this gives interesting complementary information:
Physicians considered the above study well done, reli-
able and relevant to the Czech health care environment.
Their estimates were rather conservative in comparison
to the study findings [Additional file 1: Table S7].Nurses saw the above study relevant, well done and re-
liable. Again, their estimates of the adverse drug events'
share in medication errors were rather more open and
reached almost twofold values in comparison to the
other professional groups [Additional file 1: Table S8].
Pharmacists also considered the methodology, quality of
realisation, and relevance of the above study very good.
Their estimates were rather conservative [Additional
file 1: Table S9], similar to the physicians' views.
Non-medical managers viewed the above study's meth-
odology and execution as very good, and its findings as
reliable and relevant to the Czech health care environ-
ment. Their estimates of the adverse drug events' share
in false medications rather concurred with the findings
of the study [Additional file 1: Table S10].Conclusion 2
Nearly all respondents considered the above study meth-
odologically correct, well and reliably executed, and its
results relevant to the Czech health care. Their estimates
of the adverse drug events' occurrence in Czech hospi-
tals were around, or slightly above, 7% out of all wrong
medication cases committed.Expert opinions on the economic impacts of medication
errors
A prevailing majority of respondents considered the above
study methodologically correct, well executed and relevant
to Czech hospitals. The professional estimates of an aver-
age length of extra hospitalisation due to damage caused to
patients via adverse drug events were slightly more conser-
vative in comparison to the said study, and their average
values amounted to approximately 2.6 days [Additional
file 1: Table S11].
In terms of the professional groups' view, we saw the
following opinions:
Physicians saw the above study methodologically cor-
rect, well performed and relevant to the Czech hospi-
tals. Their opinions were a bit more conservative than
those of the said study, and they reached an average level
slightly above 2.4 days [Additional file 1: Table S12].
Nurses' view was only slightly above the physicians'
view, but almost at the same level as that of the study
[Additional file 1: Table S13]. Pharmacists' view was
very similar to the other professional groups and nearly
identical with the above study [Additional file 1: Table
S14]. Non-medical managers' view on the quality and
methodology used and its relevance was apparently
positive. Their opinions on extra hospitalisation length
were the lowest ones out of the professional groups
surveyed, but it still remained above 2 days of extra
hospitalisation [Additional file 1: Table S15].
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In general, all respondents agreed on the good quality,
good execution and relevance of the above study to
Czech hospitals. They also agreed on the probability of
extra hospitalisation length exceeding 2 days and on
average reaching over 2.6 days.
Summary
The summary of findings of this survey is as follows:
1. The rate of medication error occurrence in Czech
hospitals may be rather high. Based on the
respondents' opinion, it will very probably exceed
5%! However, in a vast majority, the medication
errors have neither been recorded nor reported and,
thus, not analysed systematically.
2. Approximately at 5.01%–9.20% (or 5.00%–9.06%
after exclusion of extreme values), i.e. on average at
more than 7%, wrongly medicated patients may
suffer from serious health complications in Czech
hospitals. Consequently, a corrective therapy
requires prolongation of patient's hospitalisation,
which produces extra costs to hospitals.
3. Wrong medication, which will probably cause
patients' serious health complications and induce a
corrective therapy, may be expected to prolong
patients' hospitalisation by 2.6 days or more on
average.
The above three findings may be interpreted by means
of the following three examples:
1. In a hospital with 1,200 beds, which are occupied by
75%, hospitalisation care is provided to 900 patients.
Let us assume conservatively that each of the
patients receives seven pieces of a drug a day. That
means, they administer 6,300 pieces of a drug a day
(note that our hitherto performed analyses at major
Czech hospitals have shown that a daily average of
the drug pieces administered to patients highly
exceeds the value of seven). At least 5% or more of
the drug batches administered fail meeting, at
minimum, one of six JCI principles for a correct and
safe drug administration. That means, more than
315 wrongly administered drug batches/pieces occur
a day. In other words, a minimum of 45 patients, or
rather up to 315 of the hospital patients, may be hit
compromised by a wrong medication case every day.
2. Out of 45–315 patients who may be hit by a wrong
medication case a day, 7% may suffer from serious
health complications caused by a wrong medication.
This represents 3 to 22 patients a day!
3. Considering the above hospital and supposing that
the average length of stay, for example, is 8 days,every occupied bed will serve approximately 45
patients a year. That means that the hospital
provides hospitalisation to approximately 40,500
patients. Three to 22 patients are hit by a wrong
medication a day or approximately 1,100 to 8,000
patients experience serious health complications by
wrong medication a year. If a corrective therapy of
each of the patients damaged requires 2.6 days of
additional hospitalisation, the hospital faces—except
for the reputational and legal risks—also economic
risks in terms of additional costs. The number of
additional hospitalisation days amounts from
approximately 2,860 up to 20,800 a year. If we
multiply these numbers by costs of one hospitalisation
day, we may come from ten to several tens of millions
CZK (or EUR million) of extra costs a year. This
clearly represents a value which, along with patients'
unsafety, is worth of any hospital management's
attention.
Based on this survey results, there should not be any
doubt that the medication errors represent an important
issue for Czech hospitals' managements (as well as for
hospital managements all around the world). In terms of
the challenges calling for personalisation of medicine,
prevention of risks, increasing patients' safety, improving
therapy effectiveness, lowering costs of the health care
provided, electronic digitalisation of health care data and
innovation in health care processes, it is obvious that
elimination of errors in hospital medication is a great
topic to be addressed and supported by EU funds both
at national and—especially—Europe-wide levels.
Expert recommendations
There are still many processes in health care which have
a great potential for improvements and have not been
used so far. For this article, we have selected the topic of
medication (un)safety in European hospitals with special
attention to medication unsafety in hospitals of the
Czech Republic. The topic is closely interconnected with
patients' treatment safety, therapy effectiveness, drug
management versus polypragmasia and drug abuse, inte-
gration of pharmacists into the hospital health care
process, health care costs, computerised physician order
entry, electronic evidence of medication, electronic tra-
cing drugs administration and consumption per patient,
lowering work complexity and administrative burden of
nurses.
This article is not about inpatients' medication ther-
apy. It is, rather, about a necessary therapy of the medi-
cation processes broadly used by our public health care
providers (hospitals). The article is also about a need of
prevention of errors committed and thus harming our
inpatients. And last, but not least, it is about the price
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ineffectiveness, useless additional costs of the care and
reputation we (may) lose because of the health care
unsafety, unless we improve it soon.
It is surprising that—despite tremendous progress in
pharmaceutics, diagnostics, surgery or other medical tech-
nologies—there has been hardly any advance in medica-
tion process in Czech (European) hospitals for many
decades. As though the technology and progress avoided
the medication processes. The reality is, however, contrary
to fact that medication has a much wider choice in drugs
with much stronger treatment effects than those a couple
of years ago. However, progress in medicament efficiency
also brings much stronger, undesirable or excessive side
effects at the same time. Unfortunately, contemporary
medication is incomparably more costly than the one only
10 years ago.
Nevertheless, prescription as well as administration of
drugs is one of the most important processes in provid-
ing care in hospitals. Although these processes are rather
simple, they are considered the most risky ones in hospi-
talisation. The reason is a traditional, for many years un-
changed, process that provides too many opportunities
for occurrence of a number of errors caused by both sys-
tem imperfections and human factor failures. According
to the European Association of Hospital Pharmacists
(EAHP), the errors occur over the whole drug adminis-
tration process, while 39% of errors are made during
prescription, 12% during internal information transfer,
other 11% during internal logistics and 38% during drug
administration [33].
A traditional way of drug dispensing and administra-
tion starts with a physician's prescription of a drug to a
particular patient. Even though such a prescription is
personalised and might be made out electronically, al-
most 100% of electronic prescriptions made out in
Czech hospitals are in a non-structured text format, as
observed by the author of this article in his long-term
experience in Czech and Slovak hospitals (recently veri-
fied and repeatedly re-confirmed). It means that these
electronic prescriptions cannot serve as computerised
physician's order entry since they lack database data rec-
ord features which are necessary for further technical
elaboration in terms of computerised drug management.
No systematic check or supervision over the prescription
correctness is done. No systematic attention is paid to
patient's current physio-biochemical test results in terms
of undesirable interactions and/or suitability of a drug,
its form and dosage.
At the moment, the above described prescription
(physician's order entry) process is finished; the attend-
ing physician completely loses control over any further
drug administration or dispensing to a particular pa-
tient. The prescription of drugs to patients of a hospitaldepartment or ward is collected, usually summarised by
a ward nurse in chief, and then—as an aggregate drug
order—sent in a paper format or in an electronic text
format to the hospital pharmacy.
The hospital pharmacy—based on an aggregate order—
prepares a bulk drug shipment. The university graduate
pharmacists take over a role of an ordinary stock keeper
without any other touch on the real medication process.
When the drug shipment to a hospital medical depart-
ment or ward crosses the hospital pharmacy stock release
counter, the hospital loses any central control over the
drug stock or drug consumption. When a hospital em-
ployee takes over the drug shipment at its pharmacy stock
release counter and brings it to a ward, from then on, all
drug administration is only in the hands and on the shoul-
ders of nurses. They safe keep the drug stock on wards,
prepare individualised batches of drugs to their patients
according to physician's prescription and dispense the
drugs to the inpatients.
There is no central control over the drug stock, no
control over correctness of drug administration, no way
to trace both stock and consumption of drugs. Rather, a
sad truth in the 21st century. The blame is not on the
nurses, of course, but on the system we use. At least
20% or more of all working hours of nurses are spent on
preparing drug individual batches (consisting of mechan-
ically pressing out pills from blisters and preparing other
drug pieces into drug cups), and other 10% or more of
their working time is spent on paperworks necessary for
drug administration plus the time of dispensing drugs to
patients.
The process is naturally full of mistakes, showing fail-
ures in at least one, or rather more, of the JCI principles
of correct medication (failing in correct verification of
the right patient, right drug, right form, right time, right
way/dosage or right documentation).
Expert recommendation no. 1
Based on the above findings, it seems to be the high
time to change a traditional way of administering medi-
cation used in the new as well as the other EU member
countries' hospitals into a new type to promote persona-
lised medication, prevent medication errors, protect pa-
tients' safety, save health care costs, and contribute to
high, EU-wide standard of health care safety and
effectiveness.
The new type of hospital medication process—in com-
parison to the traditional one—looks quite different.
Most drugs fabricated in bulk may be robotically
repacked into unit-dose bags and print-labelled by
means of bar coding, or rather two-dimensional types of
coding. The prints on the bags with unit-dosed drug
comprise all information necessary about the relevant
drug in the bag (e.g. drug name, name of the producer,
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number and expiration date). A major part of the hospital
pharmacy drug and medical material stock is stored in a
‘warehouse module’ of the automated system in a form of
variously sized small bags with unit-dosed pieces of drug.
A physician prescribes therapy by means of a CPOE; a
clinical pharmacist and/or clinical pharmacologist vali-
dates the therapy order and launches automated patient
specific therapy production. Therapy is automatically
produced and delivered to the ward; a nurse verifies and
dispenses therapy by means of electronic bedside verifica-
tion of a patient, drug type, form, dosage and time of
application, and thus, she completes right electronic docu-
mentation of drug administration. Is it just a utopian vi-
sion only? Not really. Let us have a look at Figure 3.
The EAHP claims that just by means of bar coding
drugs at unit-dose packaging level, it is possible to elim-
inate over 41% of errors arising from drug administra-
tion [34,35]. Current experience shows that a modern,
innovative process as above can remove a vast majority
of all the errors occurring in the traditional way of drug
administration or dispensing, and it contributes consid-
erably to an elimination of errors in drug administration.
The other good news is that the positive effects of such
a compact, centralised, automated and fully compu-
terised drug management system change the traditional
one substantially in the following aspects:
 the computerised personal electronic order allows
for personalised medicine and tracing treatment cost
per patient,Figure 3 Flowchart of the drug administration process. improves the hospital patients' safety and both the
medical treatment process's quality and effectiveness,
 eliminates excess costs of patients' longer
hospitalisation caused by medication errors,
 decreases wards' drug stock, lowers the overall
hospital drug consumption as well as the relevant
costs, and provides the hospital management control
over important cost items,
 helps the hospital in easier winning and keeping
hospitals' accreditations and certifications,
 protects hospitals from potential legal actions taken
by patients whose health status was damaged by
wrong medication.
The problem is that changing of a long-lasting and ri-
gidly embedded process is very demanding on efforts,
courage and confidence of a hospital management. And,
it is time consuming and quite costly. In addition, many
of the above benefits of the innovative medication sys-
tem are intangible and/or not quite well visible at first
glance (safety, quality, personalised medicine, risks and
protection against potential legal actions).
The other problem is that pioneering personalised,
preventive, safety-supporting and costs-saving system
might not be very well welcome for some reasons and
especially in the countries in which there is no good
‘home-grown’ example of anything that is really func-
tioning and bringing indisputably positive results. For a
hospital management, it might be risky to start a change
which must convert the way of thinking of many col-
leagues first, which will cost a lot of time and money,
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tient therapy and cost, will add more responsibility and
involvement in medication process on pharmacists and
will free about 20% of nurses' working time by means of
eliminating their participation in preparation of indivi-
dualised drug batches to patients.Expert recommendation no. 2
Let us use the opportunity of EU international cooper-
ation for personalised, preventive and predictive medi-
cine implementation in terms of experience sharing,
know-how transfer and innovative technology imple-
mentation support. Such collaboration will show the
already-implemented innovative systems and their bene-
fits achieved in the most advanced countries. It also
gives the opportunity of experience sharing and best-
practice transfer. Data and experience exchange as well
as comparing new and traditional models internationally
brings more trust and endeavour to those who would
like to start with an implementation.
Personally, I have been engaged in an international
consulting business in public health care for more than
12 years. Three years ago, I was feeling a lack of new im-
pulses in addressing my clients with new possibilities for
improvements to hospital management and health care
service provision effectiveness. That was a momentum
which brought my consulting firm, ABC Works CZ s.r.o.
(Prague, Czech Republic), to cooperate with my colleagues
in another consulting firm HC Logic s.r.o. (experts in lo-
gistics; Ostrava, Czech Republic). We started to pursue
various issues around safety, effectiveness and economy of
medication processes in Czech hospitals and approached
various Czech hospitals' managements with our findings
and recommendations. After several studies we made for
Czech hospitals, we may say that we have got quite inter-
esting findings. For instance, there were considerable dif-
ferences in medication used by Czech hospitals compared,
for instance, with the hospitals mentioned in the reference
studies used for our opinion survey. Polypragmasia in the
Czech health care system seems to be more than an im-
portant issue. While the reference hospitals medicated
their inpatients by 7–8 units of drugs a day, the Czech
hospitals' medication administration was more than
twofold. This probably makes our health care more
costly as well as represents more risks to inpatients.
Also, the spectrum of drugs used in medication of
Czech hospitals was quite more extensive (reaching
3,000–4,000 various items in comparison to similar
hospitals in France or Germany using 2,000–2,500
items, for instance). The international collaboration
and comparing the systems used may bring new im-
pulses into a further development, new inspiration,
benchmarks and best practise dissemination.When considering a change to the traditional way of drug
administration in Czech hospitals, the decision makers have
always raised reasonable questions. Do the medication error
rates suggested by the studies performed in other countries
and different health care systems also apply to the Czech
hospitals' practice? Is this really a serious problem? Should
we invest into a change of our traditional medication
process? Does this pay off? Our survey was performed in
order to provide at least some answers to these questions.
Expert recommendation no. 3
Let us use a unique opportunity given by the European
Commission via Horizon 2020 framework programme for
the realisation of projects supporting personalised, predict-
ive and preventive medicine, including innovation in medi-
cation processes. The Horizon 2020 work programme for
years 2014–2015 declares that the Horizon 2020 societal
challenge of ‘health, demographic change and wellbeing’
(SC1) for the years 2014 and 2015 includes 34 topics in
‘personalising health and care’ focus area call. The ‘perso-
nalising health and care’ call aims to create opportunities
for real breakthrough research and radical innovation in
response to these challenges by supporting the translation
of findings into the clinic and other health and care set-
tings to improve health outcomes, reduce health in-
equalities and promote active and healthy ageing. Usage
of Horizon 2020 programme and possibly further pro-
grammes by EC for supporting EU health care develop-
ment and innovation may remove the most frequently
occurring obstacle, i.e. lack of financial sources.
The verification of personalised, predictive, preventive,
safe and efficient medication potential cannot be done
efficiently only on a national level. It needs an inter-
national cooperation, experience sharing, data exchange,
support and understanding different attitudes to medica-
tion as well as to a hospital care. The European Commis-
sion offers, by means of its programmes, e.g. Horizon 2020,
a unique opportunity to move ahead personalised, predict-
ive and preventive medicine in terms of improvements to
hospital medication safety and effectiveness. Should this
article contribute to seeking or finding good arguments for
innovation in medication process at both European-wide
and national levels and/or to support making such things
happen, this author's efforts made good sense.
Endnote
aA predictive medication here means a kind of drug
subscription predicting possible/relevant inter-reactions
of chemical components of various drugs prescribed to a
patient and administered simultaneously or within a
short period in which they may inter-react. This term
also applies to the prediction of the effects of these pre-
scribed drugs on a patient based on the current/most re-
cent patient's biochemical laboratory testing results.
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